Table 1 Evaluation of knowledge on precision medicine of rheumatologists and fellows by the use of clinical vignettes#
Vignette topics | Correct answers, N (%)* |
|---|---|
Utility of HLA-B27 testing for children of people with ankylosing spondylitis | 33/34 (97.1) |
Utility of anti-CCP antibodies research for patient with suspicion of rheumatoid arthritis | |
Diagnosis utility | 27/36 (75) |
Prognosis utility | 30/36 (83.3) |
Treatment response prediction | 14/36 (38.9) |
Absence of utility for toxicity prediction | 36/36 (100) |
Utility of TPMT test before starting treatment with azathioprine | |
Absence of utility for identification of patients who are likely to respond to azathioprine | 36/36 (100) |
Absence of utility for identification of patients who are unlikely to respond to azathioprine | 34/36 (94.4) |
Utility for identification of patients who are likely to develop neutropenia associated with azathioprine use | 28/36 (77.8) |
Populations on which to perform HLA–B* 5801 genetic test before starting allopurinol | |
Thai | 8/36 (22.2) |
Han Chinese | 20/36 (55.6) |
Korean with stage G3a chronic kidney disease or worse | 8/36 (22.2) |
Utility of HLA–B* 5801 genetic test before starting allopurinol | |
Absence of utility for identification of patients who will need higher dosage of allopurinol to reach efficacy | 36/36 (100) |
Absence of utility for identification of patients who are unlikely to respond to allopurinol | 36/36 (100) |
Utility for identification of patients who are likely to develop a hypersensitivity reaction to allopurinol | 23/36 (63.9) |